TR-Dizin İndeksli Açık & Kapalı Erişimli Yayınlar
Permanent URI for this communityhttps://hdl.handle.net/11727/10755
Browse
12 results
Search Results
Item Recommendations for Ramadan Fasting to Patients with Cardiovascular Diseases; Turkish Society of Cardiology Consensus Report(2021) Alper, Ahmet Taha; Akboga, Mehmet Kadri; Ozcan, Kazim Serhan; Tengiz, Istemihan; Turk, Ugur Onsel; Yildiz, Mustafa; Yilmaz, Mehmet Birhan; Kayikcioglu, Meral; Gazi, Emine; Yildirir, Aylin; 33960303Item Consensus paper on the evaluation and treatment of resistant hypertension by the Turkish Society of Cardiology(2020) Sahinarslan, Asife; Gazi, Emine; Sahinarslan, Asife; Gazi, Emine; Aktoz, Meryem; Ozkan, Cigdem; Okyay, Gulay Ulusal; Elalmis, Ozgul Ucar; Belen, Erdal; Bitigen, Atila; Derici, Ulver; Tutuncu, Neslihan Bascil; Yildirir, Aylin; 0000-0002-1816-3903; 0000-0001-8750-5287; 32870176; ABG-5027-2020; A-4947-2018Item 2020 ESC Core Curriculum for the Cardiologist: What has changed? Why? Should we also change our curriculum?(2020) Yildirir, Aylin; 0000-0001-8750-5287; 33257609; 33257609; A-4947-2018Item Turkish Society of Cardiology consensus report on recommendations for athletes with high-risk genetic cardiovascular diseases or implanted cardiac devices(2019) Ozel, Erdem; Kosar, Mustafa Feridun; Ozcan, Emin Evren; Hunuk, Burak; Ulus, Taner; Aytekin, Vedat; Yildirir, Aylin; Ozin, Bulent; Erdinler, Izzet; Akyurek, Omer; 0000-0001-8750-5287; 31475950; A-4947-2018Item The opinion and recommendations of Turkish Board for Accreditation in Cardiology on Board Examination(2019) Yildirir, Aylin; Altun, Armagan; Ural, Dilek; Ozdemir, Murat; Aslan, Ozgur; Muderrisoglu, Haldun; 31582681; ABB-5844-2020Item ADMA is a useful marker, but many confounding factors should be considered! Reply(2015) Bal, Ugur Abbas; Yildirir, Aylin; 25789383Item Assessment of serum hepcidin levels in patients with non-ST elevation myocardial infarction(2015) Okyay, Kaan; Yildirir, Aylin; 25625449Item The preanalytical and analytical factors responsible for false-positive cardiac troponins(2015) Okyay, Kaan; Yildirir, Aylin; 25880185Item The effect of raloxifene on left ventricular hypertrophy in postmenopausal women: A prospective, randomized, and controlled study(2015) Bal, Ugur Abbas; Atar, Ilyas; Oktem, Mesut; Zeyneloglu, Hulusi Bulent; Yildirir, Aylin; Kuscu, Esra; Muderrisoglu, Haldun; 25430415Objective: In healthy women, there is a progressive age-related increase in myocardial mass that is not seen in their male counterparts and occurs primarily in postmenopausal women. Raloxifene is a selective estrogen receptor modulator that has estrogenic actions on bone and the cardiovascular system. The aim of this study was to investigate the effect of raloxifene on myocardial hypertrophy in postmenopausal patients. Methods: A total of 22 postmenopausal osteoporotic women were included in this open-label, randomized, prospective, controlled study. Patients were randomized into two groups: 11 of the patients (group 1) were treated with raloxifene 60 mg/day, and the other 11 patients (group 2) were defined as the control group. Quantitative 2-dimensional and M-mode echocardiographic examination was performed in all patients at the beginning and repeated at the end of the 6-month follow-up period. Left ventricle mass (LVM) and left ventricle mass index (LVMI) were calculated for all patients. Results: The mean age of the patients was 57.2 +/- 3.9 years, and baseline clinical characteristics and echocardiographic parameters were similar between the two groups. After 6 months of raloxifene treatment, there was no difference in echocardiographic parameters of LVM and LVMI compared with the control group (201.2 +/- 25.9 gr vs. 169.7 +/- 46.2 gr, p=0.14 and 120.4 +/- 25.9 gr/m(2) vs. 105.5 +/- 26.3 gr/m(2), p=0.195, respectively). There was also no significant difference in LVM and LVMI in the within-group analysis of both groups. Conclusion: Raloxifene therapy does not affect myocardial hypertrophy in postmenopausal women after 6 months of treatment.Item Serum cystatin C and neutrophil gelatinase-associated lipocalin in predicting the severity of coronary artery disease in diabetic patients(2016) Okyay, Kaan; Yildirir, Aylin; Cicek, Mutlu; Aydinalp, Alp; Muderrisoglu, Haldun; 0000-0002-9635-6313; 0000-0001-8750-5287; 0000-0002-3761-8782; 0000-0001-6134-8826; 27182610; AAG-8233-2020; A-4947-2018; AAD-5841-2021; AAK-7355-2020Objective: Cystatin C and neutrophil gelatinase-associated lipocalin (NGAL) are biomarkers of renal functions. We evaluated their roles in predicting the severity of coronary artery disease (CAD). Methods: Fifty-two consecutive type 2 diabetic patients (32 males, 65.7 +/- 8.6 years) who underwent coronary angiography (CAG) for stable CAD were included in this single-center, prospective, cross-sectional study. Patients with an estimated glomerular filtration rate <60mL/min/1.73m(2) and with a history of by-pass surgery and/or coronary stent implantation were excluded. The vessel score and Gensini score were calculated to assess the presence and severity of CAD. Mann-Whitney U test, Spearman test, and multiple linear regression analysis were used for the main statistical analyses. Results: Serum cystatin C levels were higher in patients with multivessel disease than in those with single vessel disease [1260 ng/mL (953-1640) vs. 977 ng/mL (599-1114), p=0.017]. According to the median Gensini score, the higher score group also had higher cystatin C levels than the lower score group [1114 ng/mL (948-1567) vs. 929 ng/mL (569-1156), p=0.009]. However, serum NGAL levels were similar between these subgroups. There was a positive correlation between cystatin C and Gensini score (r=0.334, p=0.016). Multiple linear regression analysis revealed serum cystatin C as an independent predictor of the Gensini score (beta=0.360, t=2.311, p=0.026). These results may aid in defining cystatin C as a surrogate marker of the extent of CAD in further clinical trials. Conclusion: Serum Cystatin C, but not NGAL levels, could predict the severity of CAD in diabetic patients.